...
首页> 外文期刊>Saudi Journal of Anaesthesia >Epidural administration of ropivacaine and its effects on the pharmacodynamics of rocuronium: Randomized controlled trial. Interaction between ropivacaine and rocuronium
【24h】

Epidural administration of ropivacaine and its effects on the pharmacodynamics of rocuronium: Randomized controlled trial. Interaction between ropivacaine and rocuronium

机译:Ropivacaine的硬膜外施用及其对罗克尼鎓药效学的影响:随机对照试验。 Ropivacaine和rocuronium之间的相互作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Potentiation of neuromuscular blocking agents by local anesthetics has been described in various clinical and experimental studies. This study assessed the influence of epidural ropivacaine on pharmacodynamic characteristics of rocuronium. Design: This was a prospective randomized clinical trial at the women's hospital, an university tertiary hospital in Brazil. Sixty-two patients underwent elective abdominal surgeries requiring general anesthesia. Intervention: Patients were distributed into two groups: Group 1 (general anesthesia and epidural anesthesia) and Group 2 (general anesthesia). In Group 1, 0.2% ropivacaine at a dose of 40 mg (20 ml) was associated with 2 mg (2 ml) of morphine in a single epidural injection. The following parameters were assessed: clinical duration (DC 25 ) and time for recovery of the train-of-four (TOF) 0.9 ratio (T4/T1 = 90%) after an initial 0.6 mg/kg dose of rocuronium. The primary outcomes were DC 25 and TOF 0.9 ratio (T4/T1 = 90%). Secondary outcomes were total propofol and remifentanil consumption. Results: Values were presented as median and interquartile range. The results for DC 25 and TOF 0.9 of rocuronium were, respectively, 41.5 35.0–55.0 (25.0–63.0) in Group 1 and 44.0 37.0-51.0 (20.0–67.0) in Group 2 ( P = 0.88); 88.0 67.0–99.0 (43.0–137.0) in Group 1; and 80.0 71.0-86.0 (38.0–155.0) in Group 2 ( P = 0.83). There was no significant difference between the groups, in terms of pharmacodynamic characteristics of rocuronium. Propofol consumption did not show any difference between the groups. However, remifentanil consumption was significantly lower in Group 1 ( P 0.01). Conclusion: Epidural ropivacaine, in the dose studied, did not prolong the duration of rocuronium-induced neuromuscular blockade. Trial Registry Number: ReBEC (ref: RBR-7cyp6t).
机译:背景:在各种临床和实验研究中描述了局部麻醉剂的神经肌肉阻断剂的增强。本研究评估了硬膜外罗哌卡因对罗克铵药物动力学特征的影响。设计:这是巴西大学妇女医院妇女医院的预期随机临床试验。六十二名患者接受了一般麻醉的选修腹手术。干预:患者分为两组:第1组(全身麻醉和硬膜外麻醉)和第2组(全身麻醉)。在第1组中,在单一硬膜外注射中,在40mg(20mL)的剂量为40mg(20mL)的罗哌卡因,与2mg(2mL)的吗啡相关。评估以下参数:在初始0.6mg / kg剂量的罗孔酮后,临床持续时间(DC 25)和回收火车训练的时间(TOF)0.9比(T4 / T1 = 90%)。主要结果是DC 25和TOF 0.9比(T4 / T1 = 90%)。二次结果是总异丙酚和雷芬丹尼尔消费。结果:值作为中位数和狭窄的范围呈现。在第1组中分别为41.5 35.0-55.0(25.0-63.0)的DC 25和TOF 0.9的结果分别为41.5 35.0-55.0(25.0-63.0-51.0(第24.0-51.0-51.0(20.0-67.0)(p = 0.88); 88.0 67.0-99.0(43.0-137.0)第1组;和80.0 71.0-86.0(38.0-155.0)组(p = 0.83)。在罗科尼鎓的药物动力学特征方面,组之间没有显着差异。异丙酚消费没有显示组之间的任何差异。然而,第1组中的雷芬丹尼尔消费显着降低(P <0.01)。结论:在研究的剂量中,硬膜外罗哌啶未延长罗孔诱导的神经肌梗阻的持续时间。试用注册表号:Rebec(REF:RBR-7CYP6T)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号